Business Description
Passage Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US7027121000
Share Class Description:
PASG: Ordinary SharesDescription
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.29 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | -0.39 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 14.3 | |||||
| 3-Year EPS without NRI Growth Rate | 15.1 | |||||
| 3-Year FCF Growth Rate | 12.4 | |||||
| 3-Year Book Growth Rate | -32.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.36 | |||||
| 9-Day RSI | 79.65 | |||||
| 14-Day RSI | 74.94 | |||||
| 6-1 Month Momentum % | -46.45 | |||||
| 12-1 Month Momentum % | -3.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 5.15 | |||||
| Cash Ratio | 5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.4 | |||||
| Shareholder Yield % | -11.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -68.02 | |||||
| ROA % | -49.32 | |||||
| ROIC % | -174.49 | |||||
| ROC (Joel Greenblatt) % | -229.93 | |||||
| ROCE % | -56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 0.96 | |||||
| EV-to-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.16 | |||||
| EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.45 | |||||
| Price-to-Net-Cash | 1.53 | |||||
| Earnings Yield (Greenblatt) % | -625 | |||||
| FCF Yield % | -84.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PASG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Passage Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.17 | ||
| Beta | 0.99 | ||
| Volatility % | 136.61 | ||
| 14-Day RSI | 74.94 | ||
| 14-Day ATR ($) | 0.126881 | ||
| 20-Day SMA ($) | 0.622675 | ||
| 12-1 Month Momentum % | -3.47 | ||
| 52-Week Range ($) | 0.451 - 1.79 | ||
| Shares Outstanding (Mil) | 61.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Passage Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Passage Bio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Passage Bio Inc Frequently Asked Questions
What is Passage Bio Inc(PASG)'s stock price today?
The current price of PASG is $1.13. The 52 week high of PASG is $1.79 and 52 week low is $0.45.
When is next earnings date of Passage Bio Inc(PASG)?
The next earnings date of Passage Bio Inc(PASG) is 2025-03-04 Est..
Does Passage Bio Inc(PASG) pay dividends? If so, how much?
Passage Bio Inc(PASG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers